A National Registry on Chinese Patients With Lymphangioleiomyomatosis
Recruiting now
Conditions studied: Pulmonary Function
In brief
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
Key facts
- Study ID
- NCT03193892
- Run by
- Peking Union Medical College Hospital
- People needed
- 1500
- Starts
- 2017-01-01
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2021-09-24
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Gender: female.
- Age: no limitation.
- Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the patient.
You may not qualify if…
- Suspected LAM patients without other supporting evidence for LAM diagnosis.
- No diffuse cystic lesions in the lung.
- Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established.
- Without signed informed consent.
- Difficult to follow up.
Where it is running
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.